Penpulimab Regimens May Improve Outcomes in Resectable NSCLC

from TheBrief.Health · host TheBrief.Health

Emerging combination therapy using penpulimab, anlotinib, and chemotherapy shows promise for improving pathological response and survival outcomes in resectable non-small cell lung cancer.

Episode metadata supplied by the publisher feed · Published May 20, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Penpulimab Regimens May Improve Outcomes in Resectable NSCLC

0:00 1:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on May 20, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!